The study began with a large-scale computational sweep through publicly available blood transcriptome data. Using the limma statistical framework, the team compared gene expression in severe COVID-19 patients against healthy controls, drawing on dataset GSE171110, which comprised 44 patient samples and 10 controls. A parallel analysis of the gout dataset GSE160170, with six patients and six controls, applied the same thresholds: an adjusted p-value below 0.05 and a log2 fold change of at least 1. The COVID-19 cohort yielded 3,520 differentially expressed genes, while the gout cohort produced 1,860. Intersecting the two lists revealed just 19 genes shared by both inflammatory disorders — a compact transcriptional module that the authors interpret as the core molecular signature driving the convergent inflammatory response.

Functional enrichment analysis of these 19 shared genes pointed strongly toward the immune system. Gene Ontology terms highlighted B cell proliferation, immunoglobulin biosynthesis, cytokine activity, and cytokine receptor binding. This B-cell signal is particularly intriguing. In severe COVID-19, aberrant B cell activation and autoantibody production have been recognized as key drivers of immunopathology and lung damage. Gout, by contrast, has traditionally been viewed as a disease of innate immunity, driven by neutrophils and macrophages responding to urate crystals. Yet emerging evidence implicates B cells and autoantibody responses in chronic tophaceous gout as well. The convergence on humoral immunity in both diseases suggests a shared mechanism that has been underappreciated until now. KEGG pathway analysis further linked the shared gene set to autoimmune conditions including rheumatoid arthritis, asthma, and inflammatory bowel disease, underscoring the systemic nature of the overlapping inflammatory program.

To distill the 19 shared genes down to actionable targets, the researchers constructed a protein-protein interaction network using the STRING database at a high-confidence threshold of 0.7. The resulting network contained 19 nodes and 41 edges, with CXCL8, JUN, and IL10 showing the highest connectivity. Applying the CytoNCA plugin in Cytoscape, the team evaluated five centrality metrics — degree, closeness, eigenvector, local average connectivity, and betweenness — and identified six genes that ranked highest across all measures: CXCL8, MPO, JUN, MMP1, IL4, and IL10. These hub genes were significantly upregulated in both disease cohorts compared with healthy controls, and correlation heatmaps revealed strong positive co-expression among them in each dataset, suggesting they operate as a synergistic regulatory unit rather than isolated players.

Enrichment analysis of the six hub genes reinforced their relevance to both pathologies. Gene Ontology terms included positive regulation of MHC class II biosynthetic process, myeloid leukocyte activation, and regulation of isotype switching — processes central to adaptive immunity and implicated in the dysregulated humoral responses of severe COVID-19. KEGG pathway analysis tied the hub genes to the IL-17 signaling pathway, T cell receptor signaling, and rheumatoid arthritis. The IL-17 axis, in particular, has been independently implicated in both gout pathogenesis and COVID-19-associated hyperinflammation, positioning these six genes as convergent nodes within a shared inflammatory network.

The pivotal moment came when the team intersected these six hub genes with the predicted protein targets of colchicine, the ancient anti-inflammatory drug long used to treat acute gout attacks and recently repurposed for COVID-19 with encouraging results in trials such as GRECCO-19. Using the SwissTargetPrediction platform, the researchers generated a list of 100 putative colchicine targets from its PubChem entry. Only one of the six hub genes appeared on that list: MMP1. This single overlap suggested that colchicine’s therapeutic benefit in both diseases might flow, at least in part, through direct engagement of this matrix metalloproteinase — a mechanism not previously described.

To test this hypothesis computationally, the team performed molecular docking between colchicine and the MMP1 protein structure obtained from the Protein Data Bank. The docking simulation, run with AutoDock Vina, revealed a stable binding conformation with a calculated binding energy of −6.4 kcal/mol, a value within the range typically considered favorable for drug-target interactions. Colchicine formed conventional hydrogen bonds with the ASN-180 and ALA-182 residues of MMP1, at distances of 2.3 and 2.6 angstroms respectively, and was further anchored by a network of hydrophobic contacts within the catalytic pocket. Because these hydrogen bonds sit within the enzyme’s catalytic domain, the authors propose that colchicine binding may directly interfere with MMP1’s proteolytic activity, thereby modulating extracellular matrix remodeling and inflammatory cell migration.

Docking alone cannot guarantee that a ligand remains bound under physiological conditions, so the team followed up with a 100-nanosecond all-atom molecular dynamics simulation using GROMACS 2023 and the AMBER99SB-ILDN force field. The root mean square deviation values equilibrated within the first 10 nanoseconds and maintained a stable plateau thereafter, indicating a steady conformational state. Root mean square fluctuation analysis showed consistently low local motion across most residues, and the radius of gyration declined gradually over the first 60 nanoseconds before stabilizing around 1.46 nanometers, reflecting progressive compaction of the complex. The number of intermolecular hydrogen bonds remained steady at one to two throughout the trajectory, and comparison of snapshots at 0 and 100 nanoseconds showed no substantial dissociation or deformation of colchicine within the binding pocket. Together, these results support a durable and specific interaction between the drug and its newly identified target.

Beyond colchicine, the researchers explored a dual screening strategy for additional therapeutic candidates targeting the six hub genes. Among the top 10 predicted small molecules were simvastatin, which has established anti-inflammatory properties and has been reported to attenuate NLRP3 inflammasome activation; ciprofloxacin, a fluoroquinolone with immunomodulatory effects; and nimesulide, a selective COX-2 inhibitor that could theoretically ease gout flares, though its hepatotoxicity profile warrants caution. The team also reviewed traditional Chinese medicine formulations reported to act on the hub genes, identifying six prescriptions including Ma Xing Shi Gan Decoction, Yi-Fei-Jian-Pi-Tang, and Taodan Granules. Yi-Fei-Jian-Pi-Tang showed the broadest targeting spectrum, modulating five of the six hub genes, while Taodan Granules targeted three. The authors caution that several computational hits, such as nickel sulfate and electrocorundum, are environmental agents rather than drugs, and that all predictions require rigorous experimental validation before clinical translation.

Perhaps the most striking finding came from single-cell RNA sequencing analysis of peripheral blood mononuclear cells, drawing on datasets GSE188172 and GSE211783 and encompassing more than 94,000 cells across severe COVID-19 patients, gout patients, and healthy controls. After quality control and batch correction using Harmony integration, the team annotated eight major immune cell subpopulations and found that MMP1 expression was significantly upregulated in COVID-19 patients, with the elevation localized predominantly to B cells and plasma cells rather than myeloid compartments. This B-cell-restricted pattern was further accentuated in ventilated COVID-19 patients compared with non-ventilated cases, implying a positive correlation between MMP1 expression in B cells and disease severity. In gout patients, by contrast, MMP1 showed a more distributed expression across monocytes and macrophages, consistent with the innate immune-driven pathology of crystal-induced inflammation. The authors suggest that while MMP1 serves as a shared molecular hub at the transcriptomic level, its cellular sources and functional roles may be disease-context-dependent, and that therapeutic targeting may ultimately require cell-type-specific strategies. Taken together, the findings position MMP1 as a promising candidate for patients facing the double burden of gout and severe COVID-19, while underscoring the substantial gap that remains between computational prediction and clinical application.

Subject of Research: Shared molecular pathways between gout and severe COVID-19, focusing on MMP1 as a common hub gene and drug target

Article Title: MMP1 serves as a common link and drug target between gout and severe COVID-19 infection

Article References: Ma, H., Geng, Y., Liu, M., Feng, T., Lv, Y., Wang, H., & Niu, Y. (2026). MMP1 serves as a common link and drug target between gout and severe COVID-19 infection. Results in Chemistry, 31, Article 103967. https://doi.org/10.1016/j.rechem.2026.103967

Image Credits: AI Generated

DOI: 10.1016/j.rechem.2026.103967

Keywords: MMP1, gout, severe COVID-19, colchicine, molecular docking, molecular dynamics simulation, single-cell RNA sequencing, NLRP3 inflammasome, hub genes, bioinformatics, inflammation, drug repurposing

A nationwide retrospective cohort study from South Korea, published in the journal Heliyon, followed essentially the entire population of dialysis patients in the country during the first year vaccinations became available. The researchers, led by Jae Young Kim and Tae Ik Chang of the National Health Insurance Service Ilsan Hospital, drew on a linked database combining the Korea Disease Control and Prevention Agency’s COVID-19 records with the National Health Insurance Service, the single compulsory insurer covering every Korean citizen. Because the insurance system assigns permanent special codes to patients receiving maintenance dialysis for at least three months, the team could identify the full national population of people on hemodialysis or peritoneal dialysis with remarkable reliability.

The starting cohort included 105,323 adults on maintenance dialysis as of February 26, 2021, the day COVID-19 vaccinations began in South Korea. After excluding patients already infected with SARS-CoV-2 or lacking complete baseline data, 103,130 individuals remained under observation through December 31, 2021. Strikingly, 82.3 percent of them — 84,895 people — completed a full vaccine series during that window, a testament to the country’s policy of prioritizing dialysis patients for immunization. The vaccines used included the Pfizer-BioNTech mRNA vaccine BNT162b2, the AstraZeneca vector vaccine ChAdOx1 nCov-19, the Moderna mRNA vaccine mRNA-1273, and a tiny fraction of the single-dose Janssen vaccine Ad26.COV2.S; 42.5 percent of second doses were heterologous, meaning they mixed vaccine platforms.

To make a fair comparison, the investigators used propensity score matching, a statistical technique that pairs vaccinated and unvaccinated patients with nearly identical profiles of age, sex, income, residence, dialysis modality, dialysis duration, and a long list of comorbidities including hypertension, diabetes, heart failure, cerebrovascular disease, dementia, and cancer. Before matching, the unvaccinated group was older and sicker, reflecting hesitancy and access problems among the frailest patients. After nearest-neighbor matching with a caliper of 0.10, the final analytical cohort comprised 14,498 fully vaccinated and 14,498 unvaccinated patients with standardized differences below 0.1 on every measured characteristic — a near-perfectly balanced comparison. The average age was 63.2 years, just over half were men, roughly 89 percent were on hemodialysis, and about half had been on dialysis for five years or more.

The results were unambiguous. Over a median follow-up of 150 days, 375 participants — 1.3 percent of the matched cohort — experienced a first laboratory-confirmed SARS-CoV-2 infection, verified by positive reverse transcription polymerase chain reaction testing. Among vaccinated patients, 0.88 percent were infected, compared with 1.71 percent of unvaccinated patients. In Cox proportional hazards regression, vaccination was associated with a 53 percent lower risk of infection, corresponding to a hazard ratio of 0.47 with a 95 percent confidence interval of 0.38 to 0.58. Kaplan-Meier curves showed the cumulative incidence of infection diverging steadily between the groups throughout the observation period.

The protection against severe disease was even more pronounced. The study defined serious COVID-19 as a composite of severe infection — hospitalization requiring any form of respiratory support such as noninvasive ventilation, high-flow oxygen, or invasive mechanical ventilation, or treatment with extracorporeal membrane oxygenation or continuous renal replacement therapy — together with COVID-19-related death, meaning death during hospitalization or within 28 days of a positive test. Serious outcomes occurred in 0.26 percent of vaccinated patients versus 0.74 percent of unvaccinated patients, a hazard ratio of 0.32. Analyzed separately, severe COVID-19 was reduced by 70 percent (hazard ratio 0.30) and COVID-19-related death was likewise reduced by 70 percent (hazard ratio 0.30). In other words, even when breakthrough infections occurred after two doses, they were far less likely to turn deadly in vaccinated dialysis patients.

Subgroup analyses reinforced the message across clinically meaningful strata. The association between vaccination and lower risks of both infection and serious outcomes held consistently for patients younger and older than 65, for men and women, for those with and without diabetes or ischemic heart disease, and for those on dialysis for fewer or more than five years. This robustness matters because dialysis patients are extraordinarily heterogeneous: many carry a heavy burden of cardiovascular and metabolic disease, and longer dialysis vintage, anemia, and immunosuppressive therapy have all been linked to poorer antibody responses after mRNA vaccination.

The findings address a persistent scientific worry. Kidney failure induces immune alterations and chronic low-grade systemic inflammation, dialysis itself has immunomodulatory effects, and many patients take immunosuppressive drugs — all of which can interfere with the generation of protective immunity. Previous studies reported post-vaccination antibody levels in dialysis patients ranging from as low as 7 percent up to 66 percent of those seen in healthy controls, and a meta-analysis of 32 studies found an overall immunogenicity rate in dialysis patients of 86 percent relative to non-dialysis individuals. Yet the Korean study, which did not have antibody measurements available, demonstrates that this blunted immunogenicity does not necessarily translate into weaker clinical protection. Its results align with real-world effectiveness studies from the United States and Canada, suggesting that cellular immunity and other mechanisms may compensate for lower antibody titers. The protection observed was nonetheless more modest than the 94 percent efficacy against symptomatic infection reported in randomized trials of the general population, which had excluded nearly all patients with moderate to advanced chronic kidney disease — only 0.7 percent of trial participants had such disease.

The study’s strengths are considerable. By covering the entire national ESKD dialysis population, including home-based peritoneal dialysis patients often omitted from clinic-based research, it avoided the selection biases of single-network studies. Its time-to-event design started follow-up only after completion of the vaccine series plus a 14-day immune-response window, so the estimated risks reflect the period when vaccination would be expected to confer protection. Defining the primary outcome as laboratory-confirmed infection rather than symptomatic illness also sidestepped a practical problem: some dialysis patients cannot reliably complete symptom questionnaires because of language or cognitive limitations. Frequent RT-PCR screening, mandatory for in-center hemodialysis patients before entering their units, made undetected infections rare.

Limitations remain, and the authors are candid about them. As an observational study, residual confounding cannot be excluded; data on obesity, immunosuppressive use, dialysis adequacy, and residual kidney function were unavailable, and unmeasured risky health behaviors among the unvaccinated could have influenced censoring. The follow-up was too short to assess how long protection lasts, viral variant data were absent, and the entire study period preceded both the Omicron wave and the rollout of third booster doses, so the findings speak to the pre-Omicron era. The cohort was also entirely Korean, warranting caution when generalizing to other populations. Still, the core conclusion stands: complete COVID-19 vaccination substantially reduced the risk of SARS-CoV-2 infection, severe disease, and death in one of the pandemic’s most susceptible populations. The authors argue the evidence supports health authorities’ policies to promote and prioritize vaccination for dialysis patients, and to combat the vaccine hesitancy that has kept uptake low in some countries — a population with much to gain from a vaccine, regardless of type.

Subject of Research: Effectiveness of COVID-19 vaccination in preventing SARS-CoV-2 infection and severe outcomes in patients with end-stage kidney disease on maintenance dialysis

Article Title: Impact of COVID-19 vaccination on infection risk and clinical outcomes in patients with end-stage kidney disease undergoing dialysis: A nationwide retrospective study in South Korea

Article References: Kim, J. Y., Son, K. J., Park, P. G., & Chang, T. I. (2026). Impact of COVID-19 vaccination on infection risk and clinical outcomes in patients with end-stage kidney disease undergoing dialysis: A nationwide retrospective study in South Korea. Heliyon, 12(15), Article e45541. https://doi.org/10.1016/j.heliyon.2026.e45541

Image Credits: AI Generated

DOI: 10.1016/j.heliyon.2026.e45541

Keywords: COVID-19 vaccination, end-stage kidney disease, dialysis, SARS-CoV-2, vaccine effectiveness, South Korea, nationwide cohort study, hemodialysis, peritoneal dialysis, propensity score matching, severe COVID-19, immunocompromised patients